Accepted for/Published in: JMIR mHealth and uHealth
Date Submitted: Jun 21, 2020
Date Accepted: Sep 2, 2020
Date Submitted to PubMed: Sep 2, 2020
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Development and acceptability of a method to investigate prescription drug misuse in daily life: An ecological momentary assessment study.
ABSTRACT
Background:
Prescription drug misuse and abuse is an established public health challenge, and young adults are particularly affected. There is a striking lack of real-time, naturalistic data collection assessing intentions to misuse and other precipitating factors at the time of actual misuse, leaving unknown under what conditions individuals are most likely to misuse prescription medications. Ecological momentary assessment (EMA) applications and protocols designed to capture this information would accelerate and expand the knowledge base and could directly contribute to prevention and treatment efforts.
Objective:
The objectives in the current study were to (1) describe the development and administration of a mobile application and protocol designed to collect EMA real-time factors associated with college students’ prescription drug misuse intentions and behaviors in daily life; (2) characterize the study population who received the protocol training, including demographic information of participants who endorsed recent prescription drug misuse at screening (risk group; n = 300) and those who did not (non-risk group; n = 55); (3) present completion rates, compliance, acceptability, and reactivity associated with the EMA protocol for both risk and non-risk groups; and (4) establish initial construct validity by linking the reports of misuse behavior in daily life collected via the EMA app to prescription drug misuse reported on a standard survey.
Methods:
An EMA data collection app and protocol were designed specifically to capture hypothesized contextual factors along with prescription drug misuse intentions and behaviors in daily life. Using the protocol, young-adult college students (N = 352) completed signal- and event-contingent reports over a 28-day period. When intention to misuse a prescription drug was endorsed, a brief follow-up prompt was sent 15 minutes later to collect participants’ indications of whether or not misuse had occurred.
Results:
Risk-group participants were significantly more likely than non-risk counterparts to endorse any prescription drug misuse intentions in daily life, to complete one or more follow-up report, and to endorse any prescription drug misuse behavior in daily life on the follow-ups. Overall, participants demonstrated consistent engagement with the EMA procedures and returned an average of 74.5 reports (SD = 23.82, range 10-122). Participants in risk and non-risk groups did not differ in the number of reports they completed, the number of their reporting days, or their average completion rates. Results indicated minimal reactivity to the method. Initial construct validity was found. Participants reported uniformly positive experiences in the study and remained highly engaged throughout the reporting protocol and broader study.
Conclusions:
The novel EMA app and protocol provide an effective way to assess real-time factors associated with prescription drug misuse intentions and behavior in daily life. The resulting investigations offer the potential to provide highly translatable information for research and prevention efforts.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.